Virtual Library

Start Your Search

L. Huang

Author of

  • +

    Poster Session (ID 8)

    • Event: ACLC 2018
    • Type: Poster Session
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 11/07/2018, 00:00 - 00:00, Poster Hall
    • +

      P063 - STE029 Overcomes EGFR-TKI Resistance in Human Lung Adenocarcinoma (ID 121)

      00:00 - 00:00  |  Author(s): L. Huang

      • Abstract

      STE029 is a novel anticancer drug which consists of 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitor and novel cancer cell membrane targeting molecular. This study aimed to investigate the effect and mechanism of STE029 on overcoming the EGFR-TKI resistance in NSCLC.

      CCK8 test was used to test the cell viability and survival rate of EGFR mutated PC9 cell (Gefitinib sensitive), PC9/BB4 cell (acquired Gefitinib resistant), and EGFR wild type A549 cell after treatment of STE029, Gefitinib or combination of both. Edu test was applied to detect changes in cell cycle and Hoechst 33258 was applied to detect apoptosis rate in treatment groups. We examined the activity of EGFR/PI3K/Akt, cell cycle and apoptosis signal pathways. In vivo, nude mice were exposed to STE029, Gefitinib and STE029+Gefitinib for 5 weeks, tumor volume was measured, tumor weight was obtained on the last day. P value less than 0.05 would be considered statistically significant.

      PC9 Cells was highly sensitive to Gefitinib , while PC9/BB4 and A549 cell showed significant resistance to Gefitinib treatment, the IC50 of Gefitinib in PC9, PC9/BB4 and A549 cell was 0.12